生物
癌症研究
基因沉默
靶向治疗
乳腺癌
放射治疗
生物标志物
癌症
生物信息学
肿瘤科
内科学
医学
基因
遗传学
作者
Yu Qin,Wenhao Fu,Yang Fu,Wenjing Ye,Hong‐Hong Yan,Zecheng Yu,Ruirui Li,Yili Cai,Yuxin Chen,Lingyun Wang,Xin Wei,Yunlin Chen,Yuheng Zhang,Huazhong Ying,Furong Tang,Fangwei Dai,Han Wang
标识
DOI:10.1186/s12943-023-01808-9
摘要
Abstract Background Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the development of novel treatment options for tumours. B-cell lymphoma-2 (Bcl-2)/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) reportedly apoptosis-inducing effects in tumour cells and is associated with the progression and treatment of multiple tumours. Nevertheless, little is known about its potential role in tumour diagnosis and targeted therapy. Findings The results of the study demonstrated that the interaction of BNIP3 with HDAC1 may affect the progression of breast invasive cancer (BRCA), sarcoma (SARC), kidney renal clear cell carcinoma (KIRC), and low-grade glioma (LGG). BNIP3 seemed to exert its effects in BRCA and SARC primarily through gene silencing and integrator complex, and in KIRC and LGG, mainly by affecting olfactory function, suggesting that targeted therapy can be developed based on the above signalling pathway and downstream molecules. Interpretation BNIP3 has emerged as a promising therapeutic and diagnostic target for BRCA, SARC, KIRC, and LGG, providing new insights into tumour molecular therapies in the clinic.
科研通智能强力驱动
Strongly Powered by AbleSci AI